Antibody-drug Conjugate (ADC)(抗体-药物偶联物 (ADC))
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.
All three component parts of an ADC, the antibody, the cytotoxic agent, and the linker that joins them, are critical elements in its design. The antibody moiety should be specific for a cell surface target molecule that is selectively expressed on cancer cells, or overexpressed on cancer cells relative to normal cells. The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the intracellular concentrations achievable following distribution of the ADC into solid tumor tissue, and because only a limited number of payloads can be linked to an antibody molecule (typically an average of 3-4 payloads per antibody) without severely compromising its biophysical and pharmacokinetic properties. The cytotoxic compounds include derivatives of calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by causing DNA double-strand breaks, and derivatives of the potent antimitotic microtubule-disrupting agents, dolastatin 10 (auristatins) and maytansine.
The third vital component of an ADC is the linker that forms a chemical connection between the payload and the antibody. The linker should be sufficiently stable in circulation to allow the payload to remain attached to the antibody while in circulation as it distributes into tissues (including solid tumor tissue), yet should allow efficient release of an active cell-killing agent once the ADC is taken up into the cancer cells. Linkers can be characterized as either cleavable, or as non-cleavable.
Products for Antibody-drug Conjugate (ADC)
- Cat.No. 产品名称 Information
-
GC70007
Telisotuzumab vedotin
ABBV-399
Telisotuzumab vedotin (ABBV-399) 是一种靶向 c-Met 的抗体-药物偶联物 (ADCs)。Telisotuzumab vedotin 由 Monomethyl Auristatin E (MMAE)、Telisotuzumab 抗体和可裂解的 mc-val-cit-PABC 型 linker 偶联而成。 Telisotuzumab vedotin 可用于癌症的研究。 -
GC69393
Loncastuximab tesirine
Loncastuximab tesirine-lpyl; ADCT-402
Loncastuximab tesirine 是一种人簇分化 19 (CD19) 靶向的抗体-活性分子偶联物 (ADC)。一旦与细胞膜上的 CD19 结合,Loncastuximab tesirine 被迅速内化,引发细胞死亡。Loncastuximab tesirin 诱导细胞凋亡,可用于弥漫型 B 细胞淋巴瘤的研究。 -
GC68296
Brentuximab vedotin
维布妥昔单抗;本妥昔单抗
Brentuximab vedotin (cAC10-vcMMAE) 是一种抗体-药物偶联物 (ADC),由抗 CD30 抗体和 Monomethyl auristatin E (MMAE) 组成。Brentuximab vedotin 抑制 CD30 阳性细胞,其 IC50 值为 2.5 ng/mL。Brentuximab vedotin 可用于复发难治性霍奇金淋巴瘤的研究。
- GC65287 INX-SM-56 INX-SM-56 是一种抗 VISTA 抗体药物偶联物(anti-VISTA antibody drug conjugate),可用于抗炎药的靶向输送。VISTA:含 V 区免疫球蛋白的 T 细胞活化抑制因子。
- GC65286 INX-SM-6 INX-SM-6 可用于抗炎药的靶向输送。INX-SM-6 在 PBMCS 细胞中抑制 LPS 诱导的 IL-1β 的产生。
-
GC64930
Sacituzumab govitecan
IMMU-132
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38, showing anticancer activity. Sacituzumab govitecan has a molecular weight of 160KDa.Can be dissolved and diluted with PBS. -
GC64039
Disitamab vedotin
DISITAMABVEDOTIN(纬迪西妥单抗),RC48
Disitamab vedotin (RC48) 是一种抗体-药物偶联物 (ADC),包含抗人表皮生长因子受体2 (HER2) 的单克隆抗体,该单克隆抗体通过可降解连接子结合到细胞毒性剂 MMAE。Disitamab vedotin 增强抗肿瘤免疫。
-
GC61490
Trastuzumab emtansine
曲妥珠单抗-美坦新偶联物; Ado-Trastuzumab emtansine; PRO132365; T-DM 1
Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa. -
GC61473
Trastuzumab deruxtecan
DS-8201 (solution); DS-8201a (solution)
Trastuzumab deruxtecan(曲妥珠单抗)是一种人表皮生长因子受体2(HER2)靶向抗体-药物偶联物(ADC),由人源化抗人HER2(抗hHER2)抗体、酶促裂解肽接头和拓扑异构酶I抑制剂(DX-8951衍生物)组成。